Chantal Tasset Selected Research

Janus Kinase 1

3/2022	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
1/2021	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
1/2020	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
12/2018	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
12/2018	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
12/2018	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
1/2016	Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
8/2015	Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chantal Tasset Research Topics

Disease

11	Rheumatoid Arthritis 02/2022 - 08/2015
5	Crohn Disease (Crohn's Disease) 06/2022 - 08/2015
5	Necrosis 01/2021 - 01/2017
3	Ulcerative Colitis 03/2022 - 01/2021
2	Herpes Zoster 03/2022 - 01/2019
2	Infections 02/2022 - 01/2019
2	Ankylosing Spondylitis 01/2022 - 12/2018
2	Psoriatic Arthritis 01/2020 - 12/2018
2	Fatigue 01/2019 - 01/2018
2	Nasopharyngitis 01/2019 - 12/2018
2	Chronic Disease (Chronic Diseases) 01/2019 - 01/2018
2	Pneumonia (Pneumonitis) 12/2018 - 12/2018
1	Inflammation (Inflammations) 06/2022
1	Metaplasia 01/2022
1	Ankylosis 01/2022
1	Tuberculosis (Tuberculoses) 01/2019
1	Headache (Headaches) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Opportunistic Infections (Opportunistic Infection) 01/2019
1	Retinal Vein Occlusion 01/2019
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2018
1	Pain (Aches) 01/2018

Drug/Important Bio-Agent (IBA)

19	GLPG0634IBA 06/2022 - 08/2015
8	Janus Kinase 1IBA 03/2022 - 08/2015
5	Methotrexate (Mexate)FDA LinkGeneric 02/2022 - 01/2018
3	Biological ProductsIBA 01/2021 - 12/2018
3	Antirheumatic Agents (DMARD)IBA 01/2019 - 12/2018
2	Adalimumab (Humira)FDA Link 02/2022 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2017
2	C-Reactive ProteinIBA 01/2019 - 01/2017
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	vedolizumabIBA 01/2021
1	Tumor Necrosis Factor InhibitorsIBA 01/2021
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 12/2018
1	Pharmaceutical PreparationsIBA 12/2018
1	Creatine Kinase (Creatine Phosphokinase)IBA 12/2018
1	ametantrone (HAQ)IBA 01/2018

Therapy/Procedure

6	Therapeutics 03/2022 - 01/2018